The Optimal Antiplatelet Agent for Secondary Prevention of Coronary Artery Disease: Ring Out the Old?

J Am Coll Cardiol. 2023 Jul 11;82(2):106-108. doi: 10.1016/j.jacc.2023.05.022.

Authors

Dharam J Kumbhani¹, James A de Lemos²

Affiliations

¹ Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Electronic address: [email protected].
² Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

PMID: 37407109
DOI: 10.1016/j.jacc.2023.05.022

No abstract available

Keywords: P2Y(12) inhibitor; aspirin; coronary artery disease; meta-analysis; myocardial infarction.

Publication types

Editorial
Kommentar

MeSH terms

Aspirin / therapeutic use
Coronary Artery Disease* / drug therapy
Coronary Artery Disease* / prevention & control
Drug Therapy, Combination
Humans
Myocardial Infarction* / drug therapy
Percutaneous Coronary Intervention*
Platelet Aggregation Inhibitors / therapeutic use
Purinergic P2Y Receptor Antagonists / therapeutic use
Secondary Prevention
Treatment Outcome

Substances

Platelet Aggregation Inhibitors
Aspirin
Purinergic P2Y Receptor Antagonists